カテゴリ： GlobalData, アメリカ, 企業調査

Foundation Medicine Inc (FMI)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Foundation Medicine Inc (FMI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8014170
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月22日
◆ページ数：60
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Foundation Medicine Inc (Foundation Medicine), a subsidiary of F. Hoffmann-La Roche Ltd is a healthcare products provider that offers cancer care solutions. The company offers molecular information and cancer research programs. It offers clinical products which include FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies and sarcomas and others. It also offers additional materials, services, and real-time data through its technology products. The company partners with biotech and pharmaceutical companies to develop targeted cancer therapies and active clinical trials. Foundation Medicine is headquartered in Cambridge, Massachusetts, the US.

Foundation Medicine Inc (FMI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Foundation Medicine Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Foundation Medicine Inc, Medical Devices Deals, 2011 to YTD 2017 10
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Foundation Medicine Raises US$56 Million In Series B Financing 13
Foundation Medicine Secures Additional US$8.5 Million In Series A Venture Financing 15
Foundation Medicine Raises US$10 Million In Venture Financing 16
Partnerships 17
Bristol-Myers Squibb Enters into Agreement with Foundation Medicine 17
Epizyme Enters into Agreement with Foundation Medicine 18
Foundation Medicine Enters into Agreement with AstraZeneca 19
Foundation Medicine Partners with AstraZeneca 20
Foundation Medicine Enters into Agreement with Mirati Therapeutics 21
Foundation Medicine Extends its Co-Development Agreement with H3 Biomedicine 22
Roche Amends R&D Agreement with Foundation Medicine 23
Foundation Medicine Enters into Co-Development Agreement with Flatiron Health 24
Foundation Medicine Enters Into Distribution Agreement With Laboratorios Leti 25
Foundation Medicine Expands Co-Development Agreement With Novartis 26
Foundation Medicine Enters Into Agreement With Agios Pharma To Develop Cancer Diagnostics 27
Foundation Medicine Enters Into Agreement With AstraZeneca For Genomic Profiling 28
Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 29
Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 30
Equity Offering 31
Foundation Medicine Raises USD250 Million in Private Placement of Shares 31
Foundation Medicine Withdraws Public Offering Of Shares For Up To US$150 Million 32
Foundation Medicine Completes IPO Of Shares For US$122 Million 33
Acquisition 34
Roche Acquires Majority Stake in Foundation Medicine for USD1.03 Billion 34
Foundation Medicine Inc – Key Competitors 36
Foundation Medicine Inc – Key Employees 37
Foundation Medicine Inc – Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 39
Financial Announcements 39
Nov 01, 2017: Foundation Medicine Announces 2017 Third Quarter Results and Recent Highlights 39
Aug 01, 2017: Foundation Medicine Announces 2017 Second Quarter Results and Recent Highlights 40
May 09, 2017: Foundation Medicine Announces 2017 First Quarter Results and Recent Highlights 42
Feb 22, 2017: Foundation Medicine Announces 2016 Fourth Quarter and Year-End Results, Recent Highlights and 2017 Outlook 44
Jan 09, 2017: Foundation Medicine Reports Preliminary 2016 Results 45
Nov 02, 2016: Foundation Medicine Announces 2016 Third Quarter Results and Recent Highlights 47
Aug 02, 2016: Foundation Medicine Announces 2016 Second Quarter Results and Recent Highlights 49
May 03, 2016: Foundation Medicine Announces 2016 First Quarter Results and Recent Highlights 51
Feb 23, 2016: Foundation Medicine Announces 2015 Fourth Quarter and Year-End Results, Recent Highlights and 2016 Outlook 52
Jan 11, 2016: Foundation Medicine Reports Preliminary 2015 Results and Provides 2016 Business Outlook, including Commercial Launch of its ctDNA Assay 53
Corporate Communications 54
Oct 10, 2017: Foundation Medicine Appoints Tom Civik as Chief Commercial Officer 54
Jan 06, 2017: Foundation Medicine Announces Executive Leadership Transition 55
Oct 27, 2016: Foundation Medicine Adds Life Sciences Leader Michael R. Dougherty to its Board of Directors 56
Product News 57
Oct 18, 2016: The Leukemia & Lymphoma Society Launches Groundbreaking Precision Medicine Approach to Treat Acute Myeloid Leukemia, One of the Deadliest Blood Cancers 57
Other Significant Developments 59
Feb 25, 2016: Foundation Medicine Announces First-Ever Public Release of Broad Pediatric Data From FoundationCORE to Accelerate the Development of Precision Medicine Strategies for Pediatric Cancers 59
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60

List of Tables
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Foundation Medicine Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Foundation Medicine Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Foundation Medicine Inc, Medical Devices Deals, 2011 to YTD 2017 10
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Foundation Medicine Raises US$56 Million In Series B Financing 13
Foundation Medicine Secures Additional US$8.5 Million In Series A Venture Financing 15
Foundation Medicine Raises US$10 Million In Venture Financing 16
Bristol-Myers Squibb Enters into Agreement with Foundation Medicine 17
Epizyme Enters into Agreement with Foundation Medicine 18
Foundation Medicine Enters into Agreement with AstraZeneca 19
Foundation Medicine Partners with AstraZeneca 20
Foundation Medicine Enters into Agreement with Mirati Therapeutics 21
Foundation Medicine Extends its Co-Development Agreement with H3 Biomedicine 22
Roche Amends R&D Agreement with Foundation Medicine 23
Foundation Medicine Enters into Co-Development Agreement with Flatiron Health 24
Foundation Medicine Enters Into Distribution Agreement With Laboratorios Leti 25
Foundation Medicine Expands Co-Development Agreement With Novartis 26
Foundation Medicine Enters Into Agreement With Agios Pharma To Develop Cancer Diagnostics 27
Foundation Medicine Enters Into Agreement With AstraZeneca For Genomic Profiling 28
Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 29
Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 30
Foundation Medicine Raises USD250 Million in Private Placement of Shares 31
Foundation Medicine Withdraws Public Offering Of Shares For Up To US$150 Million 32
Foundation Medicine Completes IPO Of Shares For US$122 Million 33
Roche Acquires Majority Stake in Foundation Medicine for USD1.03 Billion 34
Foundation Medicine Inc, Key Competitors 36
Foundation Medicine Inc, Key Employees 37
Foundation Medicine Inc, Other Locations 38

★海外企業調査レポート[Foundation Medicine Inc (FMI)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Western Digital Corporation：企業の戦略・SWOT・財務情報
    Western Digital Corporation - Strategy, SWOT and Corporate Finance Report Summary Western Digital Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • TOTAL S.A.：企業の戦略・SWOT・財務情報
    TOTAL S.A. - Strategy, SWOT and Corporate Finance Report Summary TOTAL S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Sonoco Products Co (SON)：企業の財務・戦略的SWOT分析
    Sonoco Products Co (SON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • SIFI SpA：企業の戦略的SWOT分析
    SIFI SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • Jyoti Structures Ltd (JYOTISTRUC)：企業の財務・戦略的SWOT分析
    Jyoti Structures Ltd (JYOTISTRUC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • International Dairy Queen, Inc.：企業の戦略・SWOT・財務情報
    International Dairy Queen, Inc. - Strategy, SWOT and Corporate Finance Report Summary International Dairy Queen, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • DHL Supply Chain (formerly Exel Inc.)：戦略・SWOT・企業財務分析
    DHL Supply Chain (formerly Exel Inc.) - Strategy, SWOT and Corporate Finance Report Summary DHL Supply Chain (formerly Exel Inc.) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Eddingpharm Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Eddingpharm Inc (Eddingpharm) is a pharmaceutical company that manufactures and distributes medicines. The company develops products in therapeutic areas such as clinical nutrition, antibiotics, respiratory system, nephrology and cardiovascular. It offers antibiotics including vancocin, cecl …
  • RegenxBio Inc (RGNX)：企業の財務・戦略的SWOT分析
    RegenxBio Inc (RGNX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • B. Braun Medical Inc：医療機器：M&Aディール及び事業提携情報
    Summary B. Braun Medical Inc (B. Braun), a subsidiary of B. Braun Melsungen AG, is a medical device company that provides infusion therapy and pain management technology, products and services. The company’s product portfolio includes TPN compounding bags, parenteral nutrition additives, closed syst …
  • Kerr Corp：企業の戦略的SWOT分析
    Kerr Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Collegium Pharmaceutical Inc (COLL)-医療機器分野：企業M&A・提携分析
    Summary Collegium Pharmaceutical Inc (Collegium) is a healthcare products provider that develops chronic pain and oral drug delivery solutions. The company's lead candidate, Xtampza ER, is an abuse-deterrent, extended-release, oral formulation of oxycodone that uses DETERx technology for the long-te …
  • CVRx Inc：医療機器：M&Aディール及び事業提携情報
    Summary CVRx Inc (CVRx) is a medical device company that develops and designs implantable device. The company provides barostim neo system, which is designed to trigger the body’s natural blood flow regulation system to treat high blood pressure and heart failure. Its products are used in the treatm …
  • Park Hotels & Resorts Inc (PK)：企業の財務・戦略的SWOT分析
    Park Hotels & Resorts Inc (PK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Wolverine World Wide, Inc.：企業の戦略・SWOT・財務情報
    Wolverine World Wide, Inc. - Strategy, SWOT and Corporate Finance Report Summary Wolverine World Wide, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Celsion Corp (CLSN)-医療機器分野：企業M&A・提携分析
    Summary Celsion Corp (Celsion) is an oncology company that focuses on developing a portfolio of new cancer treatments, including directed chemotherapies, RNA based therapies and DNA-mediated immunotherapy. The company’s three platform technologies including Lysolipid Thermally Sensitive Liposomes (L …
  • Alnylam Pharmaceuticals Inc (ALNY)：医療機器：M&Aディール及び事業提携情報
    Summary Alnylam Pharmaceuticals Inc (Alnylam) is a biopharmaceutical company which discovers, develops and commercializes therapeutics based on Ribo Nucleic Acid interference (RNAi). The company offers a broad pipeline of investigational RNAi therapeutics in the areas of genetic medicines, hepatic i …
  • EPAM Systems Inc (EPAM)：企業の財務・戦略的SWOT分析
    EPAM Systems Inc (EPAM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • The Hong Kong and China Gas Co Ltd (3)：石油・ガス：M&Aディール及び事業提携情報
    Summary The Hong Kong and China Gas Company Limited (Towngas) is an energy company that produces distributes and markets the gas, water and related activities in Hong Kong and China. The company also carries out the LPG filling stations and utilization of landfill gas. The company has interests in v …
  • Cellmid Ltd (CDY)：製薬・医療：M&Aディール及び事業提携情報
    Summary Cellmid Ltd (Cellmid), formerly Medical Therapies Ltd, is a life sciences company that develops and commercializes diagnostic and therapeutic products. The company holds comprehensive portfolio of intellectual property relating to the novel targets midkine and FGF5. It offers products such a …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆